Home > Riviste > Minerva Medica > Fascicoli precedenti > Articles online first > Minerva Medica 2018 Jan 31

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

MINERVA MEDICA

Rivista di Medicina Interna


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,878


eTOC

 

Minerva Medica 2018 Jan 31

DOI: 10.23736/S0026-4806.18.05435-6

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Treatment rate for HCV in the direct acting antivirals era in HIV co-infected patients: data from an italian cohort

Gianluca CUOMO , Cinzia PUZZOLANTE, Claudia LAZZARETTI, Giovanni GUARALDI, Vanni BORGHI, Cristina MUSSINI

Clinic of Infectious Diseases, AOU Policlinico di Modena, Modena, Italy


PDF  


BACKGROUND: New Direct Antiviral Agents (DAA) are now effective in HCV infection; persons living with HIV (PLWH) were undertreated. Aim of this study was to describe the management of HCV treatment in a HIV/HCV cohort during a 16 years period.
METHODS: An electronic review of all HIV patients with > 1 clinic check from the year 2000 was made. De- mographic, virologic and treatment data were collected.
RESULTS: From 2000 to 2015 a total of 2352 PLWH were enrolled; 776 (33%) resulted positive at HCV anti- bodies, and were mostly genotype 1 and 3. 279/579 (48.2%) were treated, and 170 (29.3% of total, 60.9% of treated) obtained a SVR. Treatment rate for HCV had a significant increase in the 2015 (20.6%, p<0.05 when compared with previous years). SVR rate was significantly improved in the 2015 (P<0,05 when com- pared with each single previous year). At univariate analysis among the different year group there were sig- nificant differences in term of HCV RNA positive pts (P<0.001), number of treated (total) and naïve pa- tients (P<0.001 in each of cases), SVR rate ( P<0.001), mortality rate (P=0.003). HCV-Ab positive pts with HCV-RNA not detectable (cured) increased during years. At 2015, 50.4% of the HCV-Ab positive pts re- sulted to be HCV-RNA negative.
CONCLUSIONS: In the DAA’s era a significant increase in the number of treatments was observed. SVR rate was significantly higher. Treatment rate still remains quite low. More than a half of our population of HCV co-infected patients results to be cured for HCV.


KEY WORDS: Hepatitis C - HIV - HCV - Hepatitis treatment - Cascade

inizio pagina

Publication History

Article first published online: January 31, 2018
Manuscript accepted: January 24, 2018
Manuscript revised: January 15, 2018
Manuscript received: September 21, 2017

Per citare questo articolo

Cuomo G, Puzzolante C, Lazzaretti C, Guaraldi G, Borghi V, Mussini C. Treatment rate for HCV in the direct acting antivirals era in HIV co-infected patients: data from an italian cohort. Minerva Med 2018 Jan 31. DOI: 10.23736/S0026-4806.18.05435-6

Corresponding author e-mail

cuomo.gianluca@policlinico.mo.it